2023 Guidance and Q3 Earnings

Spotlight on prevention: Vaccines are a strong, durable growth business Launched world's first RSV vaccine, £709m in Q3 AREXVY (RESPIRATORY SYNCYTIAL VIRUS VACCINE, ADJUVANTED) • Approved in US, EU, Canada, Japan Positive data in 50-59-year-old adults. Shingrix £825m +15% in Q3 100% efficacy in large, study in China Partnership with Zhifei expands potential in China Launched in 39 countries. 回 SHINGRIX (ZOSTER VACCINE RECOMBINANT, ADJUVANTED) Large vaccines pipeline with outstanding capabilities in technology platforms 18 vaccines in clinical development • Substantial innovation and comprehensive suite of vaccine platform technologies, including next-generation mRNA and MAPS GSK 6

View entire presentation